The new instrument will be used for frozen aliquotting of a wide range of sample types, including tissue, feces, plasma, whole blood, urine and other biofluids.

CXT 353, which includes a compact benchtop design and touch screen operation, is compatible with a wide range of vial types.

CryoXtract business development and marketing vice-president Graham Long said: "This is a welcome expansion to our product line that will especially meet the needs of researchers working with labile molecules.

The instrument will provide increased range of aliquot volumes (10-250µL) and prevent sample-to-sample carryover and contamination. Its 1.5 mm single-use coring probe enables smaller core volumes for targeted tissue acquisition.

The laser-targeting feature of the instrument will allow coring of specific tissue sample regions and streamlining tissue processing within pathology workflows.

CryoXtract CEO Dan Espinal said: "The CXT 353 platform was developed in response to the needs of our customers and is a manifestation of our commitment to designing the best products on the market."

The firm also produces CXT 750 Automated Frozen Sample Aliquotter, which is claimed to accurately acquire specific and user-defined volumes from frozen samples.

CryoXtract will showcase its products, including CXT 353, at the annual meeting of the Association for Molecular Pathology (AMP) in Austin, US, which will be held from 5 to 7 November.